BioRestorative Therapies announced that it has completed enrollment for the safety run-in component of its Phase 2 clinical study of BRTX-100 targeting patients suffering from chronic lumbar disc disease. BRTX-100 is the Company’s lead clinical candidate, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. BRTX-100 is currently being evaluated in connection with a Phase 2 clinical trial to treat cLDD. The trial is prospective, randomized, double-blinded and controlled. The trial will evaluate the safety and preliminary efficacy of a single dose of BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 clinical sites in the United States to receive either the investigational drug or control in a 2:1 fashion.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BRTX:
- BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100
- BioRestorative Therapies to seek FDA approval to expand BRTX-100 application
- BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100
- BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023
- BRTX Blasts Up with New Patent
